Diasorin SpAWBO:DIAS -4.14%74 Return-on-Tangible-Asset is 6.88% as of Dec. 2025, which is 70% below its 10-year median of 22.77. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.10 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 83.26% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Diasorin SpA's annualizedNet Income for the quarter that ended in Dec. 2025 was €74 Mil. Diasorin SpA's average total tangible assets for the quarter that ended in Dec. 2025 was €1,083 Mil. Therefore, Diasorin SpA's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 6.88%.
The historical rank and industry rank for Diasorin SpA's Return-on-Tangible-Asset or its related term are showing as below:
WBO:DIAS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.84 Med: 22.77 Max: 31.32
Current: 12.17
During the past 13 years, Diasorin SpA's highest Return-on-Tangible-Asset was 31.32%. The lowest was 11.84%. And the median was 22.77%.
WBO:DIAS's Return-on-Tangible-Asset is ranked better than 83.26% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs WBO:DIAS: 12.17
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Diasorin SpA Return-on-Tangible-Asset Related Terms
Diasorin SpA Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:DIAS vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 6.88% mean?
Diasorin SpA (WBO:DIAS) has a Return-on-Tangible-Asset of 6.88% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diasorin SpA and its competitors. This is 70% below median its historical median of 22.77. Over the past decade, Diasorin SpA's Return-on-Tangible-Asset has ranged from 11.84 to 31.32. According to the industry distribution chart, Diasorin SpA ranks #36 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is Diasorin SpA's Return-on-Tangible-Asset too high?
Diasorin SpA's current Return-on-Tangible-Asset of 6.88% is 70% below median its 10-year median of 22.77. Over the past 10 years, this metric has ranged from a low of 11.84 to a high of 31.32. Based on the distribution chart, Diasorin SpA ranks #36 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #36 out of 215 companies for Return-on-Tangible-Asset. This places Diasorin SpA in the top 17% of its industry — outperforming the majority of peers. Historically, Diasorin SpA's own Return-on-Tangible-Asset has ranged from 11.84 to 31.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Return-on-Tangible-Asset is 6.88%, which is 70% below median its own 10-year median of 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.10, compared to a current price of €67.18 — trading 25.4% below its estimated fair value. The current Return-on-Tangible-Asset is 6.88%, which is 70% below median its 10-year median of 22.77. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Return-on-Tangible-Asset is 6.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €67.18 is trading 25.4% below its estimated GF Value™ of €90.10.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
Return-on-Tangible-Asset: 6.88% (70% below median its 10-year median of 22.77)
GF Value™: €90.10 vs. price of €67.18 (25.4% below fair value)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
